Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALPI | P09923 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650091 | 0.92 | BLM (0.47) | BLMMEN1KMT2AMAPTKDM4E | |
| SCHEMBL13650106 | 0.87 | SIRT1 (0.49) | MEN1KMT2ASIRT1MAPTKDM4E | |
| SCHEMBL13650083 | 0.82 | CFTR (0.49) | MEN1KMT2ASIRT1POLBHIF1A | |
| SCHEMBL13650086 | 0.78 | MEN1 (0.45) | BLMMEN1KMT2ASIRT1MAPT | |
| SCHEMBL13650099 | 0.77 | MEN1 (0.44) | BLMMEN1KMT2ASIRT1MAPT | |
| SCHEMBL14082172 | 0.73 | MAPT (0.53) | MEN1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL13650092 | 0.71 | SIRT1 (0.48) | MEN1KMT2ASIRT1MAPTKDM4E | |
| SCHEMBL13650095 | 0.70 | MEN1 (0.43) | MEN1KMT2ASIRT1MAPTKDM4E | |
| SCHEMBL1669669 | 0.69 | MAPT (0.68) | BLMMEN1KMT2AMAPTKDM4E | |
| SCHEMBL1669671 | 0.69 | MAPT (0.68) | BLMMEN1KMT2AMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | BLM 1540/4885MEN1 4189/4885KMT2A 3845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.